Canadian Phase 2 Trial • Health Canada Approved
MEDIA
HULC in the News
Stories highlighting the research, milestones, and families behind the HULC clinical trials.
Two decades in the making — world-first trial aims to heal the lungs of preemies | 01-06-2024
This story highlights the journey of baby Emmy, born at 23 weeks of gestation and weighing just over 500 grams, who became the first infant in North America to receive mesenchymal stromal cell therapy as part of the HULC-1 clinical trial.
First patient treated in world-first cell therapy trial to heal the lungs | 24-04-2024
In this article, the Ottawa Hospital Research Institute announced the launch of the HULC-1 trial, the first study worldwide to test umbilical cord–derived mesenchymal stromal cells (MSCs) in premature infants with severe lung disease (bronchopulmonary dysplasia, or BPD). This milestone marks a major step toward developing safe, regenerative treatments to help the most fragile newborns breathe easier.
Tiny trailblazer: First baby treated in world-first trial for chronic lung disease | 19-01-2024
This story celebrates the first baby successfully treated in the HULC-1 study and highlights how the Ottawa Hospital team carefully prepared and delivered this innovative therapy.
'Very emotional moment': Ottawa preemie becomes the first in world to receive stem cell treatment in clinical trial | 18-01-2024
This Ottawa Citizen article highlights baby Emmy — born at 23 weeks and weighing just over 500 g — who became the first infant worldwide to receive the innovative cell treatment being tested for chronic lung disease in premature babies. It captures how the moment marked the culmination of nearly 20 years of research by Dr. Bernard Thébaud’s team and underscores the hope this trial brings to families of extremely preterm infants.
Ottawa doctor to launch clinical trial to explore treatment of chronic lung disease in infants | 28-06-2022
This article features Dr. Bernard Thébaud and his team as they prepare to launch the world’s first clinical trial testing umbilical-cord–derived mesenchymal stromal cells (MSCs) in premature infants with severe lung disease. It shares the story of the families and researchers behind the study, highlighting the hope that this innovative therapy could one day prevent or reduce bronchopulmonary dysplasia (BPD) and improve the lives of vulnerable newborns.
